02:21 , Mar 29, 2019 |  BC Innovations  |  Targets & Mechanisms

AACR moves in a myeloid direction

Myeloid cells are showing up everywhere at this year’s AACR conference, suggesting the research community is rapidly expanding the ways it can harness the cell types to improve cancer immunotherapy responses. One of those ways...
21:37 , Feb 14, 2019 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: January 2019

New Therapeutic Targets and Biomarkers: January 2019 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during January. Therapeutic targets are defined as any protein, gene or other molecule...
13:47 , Jan 3, 2019 |  BC Innovations  |  Distillery Therapeutics

Renal

INDICATION: Renal damage Mouse studies suggest inhibiting AKR1A1 or PKM2 could help treat acute kidney injury (AKI). In a mouse model of AKI, systemic AKR1A1 knockout or renal-specific PKM2 knockout increased survival and decreased tubular...
04:21 , Nov 30, 2018 |  BC Innovations  |  Targets & Mechanisms

Adhesion targets emerge at ASH 2018

The next wave of targets in blood cancers and hematology will come from adhesion molecules, innate immune cells and regulators of gene expression, according to BioCentury’s analysis of emerging targets at ASH 2018. BioCentury’s analysis...
19:54 , Jun 9, 2017 |  BC Week In Review  |  Company News

Threshold grants OBI ex-Asian rights to TH-3424

OBI Pharma Inc. (TPEx:4174) acquired ex-Asian development and commercialization rights to OBI-3424 (formerly TH-3424) from Threshold Pharmaceuticals Inc. (NASDAQ:THLD) for an undisclosed upfront payment. OBI receives rights worldwide, excluding Taiwan, Japan, South Korea, Singapore, Malaysia,...
21:09 , Dec 30, 2016 |  BC Week In Review  |  Company News

Threshold, NIH deal

Threshold and NIH’s NCI partnered to conduct preclinical testing assessing the biotech’s TH-3424 (AST-106) against T cell acute lymphoblastic leukemia (ALL) xenograft cell lines, which highly express aldo-keto reductase family 1 member C3 (AKR1C3) ....
18:32 , Nov 18, 2016 |  BC Week In Review  |  Clinical News

Tarloxotinib: Development discontinued

Threshold discontinued development of tarloxotinib after reporting interim data from the Phase II TH-CR-601 and TH-CR-602 trials of the compound to treat NSCLC and squamous cell carcinoma of the head and neck (SCCHN) or skin...
18:26 , Nov 18, 2016 |  BC Week In Review  |  Clinical News

Tarloxotinib: Development discontinued

Threshold discontinued development of tarloxotinib after reporting interim data from the Phase II TH-CR-601 and TH-CR-602 trials of the compound to treat non-small cell lung cancer (NSCLC) and squamous cell carcinoma of the head and...
08:00 , Feb 9, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Prostate cancer Aldo-keto reductase family 1 member C3 (AKR1C3) In vitro studies identified specific AKR1C3 inhibitors that could help treat castration-resistant prostate cancer. AKR1C3 is...
07:00 , Jul 23, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Brain cancer Polymerase (DNA directed), delta 2, regulatory subunit 50kDa (POLD2); cytochrome c, somatic (CYCS); metallothionein 1A (MT1A; MTC); aldo-keto reductase family 1, member C3...